486 related articles for article (PubMed ID: 32698317)
1. Monoclonal Antibodies in Cancer Therapy.
Zahavi D; Weiner L
Antibodies (Basel); 2020 Jul; 9(3):. PubMed ID: 32698317
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Antibodies in Cancer Therapy.
Gasser M; Waaga-Gasser AM
Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies for the treatment of cancer.
Shuptrine CW; Surana R; Weiner LM
Semin Cancer Biol; 2012 Feb; 22(1):3-13. PubMed ID: 22245472
[TBL] [Abstract][Full Text] [Related]
4. Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.
Franssen LE; Stege CAM; Zweegman S; van de Donk NWCJ; Nijhof IS
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32331242
[TBL] [Abstract][Full Text] [Related]
5. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
7. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy.
Zahavi D; AlDeghaither D; O'Connell A; Weiner LM
Antib Ther; 2018 Jun; 1(1):7-12. PubMed ID: 33928217
[TBL] [Abstract][Full Text] [Related]
8. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.
Chester C; Marabelle A; Houot R; Kohrt HE
Curr Opin Immunol; 2015 Apr; 33():1-8. PubMed ID: 25576932
[TBL] [Abstract][Full Text] [Related]
9. Photothermal therapies to improve immune checkpoint blockade for cancer.
Balakrishnan PB; Sweeney EE; Ramanujam AS; Fernandes R
Int J Hyperthermia; 2020 Dec; 37(3):34-49. PubMed ID: 33426992
[TBL] [Abstract][Full Text] [Related]
10. [Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review].
Qu YH; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1370-5. PubMed ID: 21129296
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
12. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.
Lo Nigro C; Macagno M; Sangiolo D; Bertolaccini L; Aglietta M; Merlano MC
Ann Transl Med; 2019 Mar; 7(5):105. PubMed ID: 31019955
[TBL] [Abstract][Full Text] [Related]
13. Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy.
Riller Q; Varthaman A; Sibéril S
Adv Exp Med Biol; 2020; 1277():127-141. PubMed ID: 33119870
[TBL] [Abstract][Full Text] [Related]
14. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
[TBL] [Abstract][Full Text] [Related]
15. Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer.
Park M; Kim JW
Toxicol Res; 2024 Jul; 40(3):335-348. PubMed ID: 38911540
[TBL] [Abstract][Full Text] [Related]
16. Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.
Behrens LM; van den Berg TK; van Egmond M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884427
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies: versatile platforms for cancer immunotherapy.
Weiner LM; Surana R; Wang S
Nat Rev Immunol; 2010 May; 10(5):317-27. PubMed ID: 20414205
[TBL] [Abstract][Full Text] [Related]
18. Innovative Therapy, Monoclonal Antibodies and Beyond.
Di Nicola M; Apetoh L; Bellone M; Colombo MP; Dotti G; Ferrone S; Muscolini M; Hiscott J; Anichini A; Pupa SM; Braud F; Del Vecchio M
Cytokine Growth Factor Rev; 2017 Dec; 38():1-9. PubMed ID: 29029813
[TBL] [Abstract][Full Text] [Related]
19. [Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody].
Shimodaira H; Komine K; Soeda H; Ishioka C
Gan To Kagaku Ryoho; 2010 May; 37(5):795-8. PubMed ID: 20495309
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
